Enregistrement - Lobbyistes salariés d'entreprises

Objets

• Commerce international
• Développement économique
• Développement international
• Développement régional
• Industrie
• Propriété intellectuelle
• Santé
• Sciences et technologies

Détails sur l'objet

Politique ou Programme

• Health Canada regarding the development and implementation of an approval pathway for Subsequent Entry Biologics (SEBs)
• Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Product Directorate to meet performance targets for the review of generic drug submissions.
• Health Canada, Industry Canada and International Trade to address fundamental flaws with respect to Canada's Access to Medicines Regimes
• Health Canada, Industry Canada, and International Trade Canada regarding effective measures to combat counterfeit drugs in Canada and around the world.
• Industry Canada's science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation.

Proposition législative, Projet de loi ou résolution

• Health Canada regarding the modernization of the Food and Drug Act (formerly Bill C-51) with respect to the development and implementation of a Progressive Licensing Framework for pharmaceuticals.
• Industry Canada regarding export provisions of the Patent Act (pharmaceuticals)
• Industry Canada with respect to the Patent Act as it pertains to pharmaceuticals.
• Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property

Règlement

• Canadian Generic Pharmaceutical Association's ("CGPA") legal challenge of the 2006 Amendments to Health Canada's Food and Drug Regulations with respect to Data Exclusivity.
• Industry Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.

Techniques de communication

• Communication écrite
• Communication orale
• Appel au grand public

Institutions gouvernementales

• Affaires étrangères et Commerce international Canada (MAECIC)
• Agence canadienne de développement international (ACDI)
• Agence du revenu du Canada (ARC)
• Conseil d'examen du prix des médicaments brevetés (CEPMB)
• Finances Canada (FIN)
• Industrie Canada
• Instituts de recherche en santé du Canada (IRSC)
• Justice Canada (JC)
• Patrimoine canadien (PCH)
• Santé Canada (SC)
• Secrétariat du Conseil du Trésor du Canada (SCT)
• Solliciteur général Canada (SGC)
• Tribunal canadien du commerce extérieur (TCCE)
• Tribunal de la concurrence (TC)

Adresse :
6111 Royalmount avenue, suite 100
Montreal, QC  H4P 2T4
Canada

Numéro de téléphone : 514-340-9800
Numéro de fax : 514-342-3654  

Renseignements sur la société mère